Uncategorized
Positive results seen for KPI-121 in treatment of inflammation, pain after cataract surgery
A confirmatory phase 3 trial of KPI-121 for the treatment of inflammation and pain in patients who have undergone cataract surgery has shown positive top-line results, according to a press release from Kala Pharmaceuticals.KPI-121 1% was dosed twice a day for 2 weeks in a 520-patient, multicenter, randomized, double-masked, placebo-controlled, parallel-group trial and showed statistical significance for both of its primary efficacy endpoints and all of its secondary endpoints vs. placebo, the release said.